The MM+M Podcast

The MM+M Podcast

MM+M editors Jameson Fleming, Jack O'Brien, Bella Czajkowski, Lecia Bushak, and Steve Madden speak with people of note in and around the healthcare marketing world, and chat about news impacting the sector. New episodes released each week.

  1. 3d ago

    Rethinking GLP-1 messaging and reviewing the FDA's peptide panel

    Executive editor Jack O’Brien first met Wendy Lund, an honoree from our Pinnacle Awards and Women of Distinction program, in September of 2022. Lund had just left her position as CEO of Agency 100 honoree GCI Health to serve as chief client officer for health and wellness at WPP. Now in her new post as CEO of Stagwell-owned agency Allison, Lund joins this week’s podcast for an in-person interview with reporter Bella Czajkowski. Lund dives into a recent HarrisX–Allison Worldwide study on how GLP-1s are reshaping attitudes toward weight loss and care.  The report was released late last month and chief among its numerous findings was the observation that GLP-1s have moved firmly into the mainstream, though the public conversation around them remains split between medical breakthrough and moral judgment. As Wendy told Bella, “culture is shaping health, but health is also shaping culture.” And for our Trends segment, O’Brien and Czajkowski are joined by editor-at-large Steve Madden for a conversation on all that went down during the FDA’s recent two-day advisory panel focused on peptides.  Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Rethinking GLP-1 messaging and reviewing the FDA's peptide panel
  2. Jul 22

    Novartis going on 30: Inside the Swiss pharma giant's corporate brand evolution

    Thirtieth birthdays are among the most reflective celebrations that we have. Born out of one of the largest corporate mergers in history, Novartis was founded in 1996 and celebrated its 30th anniversary this year. As such, the Swiss pharma giant is reflecting on its corporate branding down to the color palette as it eyes a future where its R&D operations lead to new drugs on the market targeting a host of disease states and medical conditions. In order to articulate its mission and underscore how it has evolved from a marketing perspective, Novartis is taking a look back before it sets its eyes on the future. This week’s episode features reporter Bella Czajkowski in conversation with Novartis’ chief corporate affairs officer Michelle Weese. The pair discuss the history of Novartis, how it is recognizing its 30 years in business and what we can expect from the drugmaker as it relates to marketing in the months and years ahead. And for our Trends segment, executive editor Jack O’Brien is joined by editor-at-large Steve Madden and pharma editor Lecia Bushak to talk through the FDA’s proposed de facto pharma ad ban now that the dust has settled — at least a little bit.  Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Novartis going on 30: Inside the Swiss pharma giant's corporate brand evolution
  3. Jul 16

    Health brands take the pitch at the 2026 FIFA World Cup: Where the world comes to play

    Whether you call it soccer or football, people all around the world love the “beautiful game” – including health brands.  When the 2026 FIFA World Cup kicked off about a month ago across 16 locations in North America, there were 48 teams competing for the gold trophy.  But more importantly for our sake, there were also several major health brands marketing and advertising throughout the five week tournament, including provider organizations and drugmakers.  Bristol Myers Squibb launched its We Won’t Lose media campaign in mid-June and has served as an official supporter of New York New Jersey as a host city.  Similarly, its Big Pharma rival Sanofi served as an official supporter of Boston as a host city, while consumer health company Haleon served as the official consumer healthcare product partner of U.S. Soccer. The World Cup has been the main attraction for weeks now, so as it comes to a dramatic close in the coming days, our summer intern Lola Offenback brings us a jumbo World Cup episode with back-to-back interviews.  First up is Opeyemi Oluwole-Sowore, chief marketing officer at Hackensack Meridian Health, who details how the New Jersey-based health system has served as an official supporter of New York New Jersey as a host city. Then, you’ll hear from Cologuard’s marketing director Tara Cunningham about how the Exact Sciences brand produced its Halftime ad featuring U.S. women’s soccer stars Abby Wambach and Julie Foudy. Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Health brands take the pitch at the 2026 FIFA World Cup: Where the world comes to play
  4. Jul 2

    2026 Women of Distinction keynote on the investment opportunity in women’s health

    The science on women’s health is still brand new. Women have up to twice the rate of side effects from drugs compared to men, but were only federally required to be included in clinical research in 1993. On the policy front, there’s a 30% lower reimbursement rate for female patients. And only 8 to 10% of the NIH’s funding budget goes to women’s health research, despite women making up half of the population. MM+M’s 2026 Women of Distinction keynote touched on all of these issues – the emerging science on women’s health, the disparities and gaps that still remain, and how this signals a massive opportunity for investment, drug innovation and marketers. This week, we’re bringing the full audio of the keynote to you, featuring Jessica Federer, managing director of the Women’s Health Fund and former Bayer Chief Digital Officer, as well as Liz Powell, founder of G2G Consulting and Women’s Health Advocates. They delve into the ways healthcare and pharma marketers have a pivotal role to play in changing the statistics and paving a new road forward for women’s health. Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    2026 Women of Distinction keynote on the investment opportunity in women’s health
  5. Jul 1

    Can Noom rediscover its ad spend glory?

    When you look across the vast, ever-expanding GLP-1 landscape, you see a handful of key players with different services offered. One of them is Noom, which attempts to differentiate itself from other telehealth shops by billing itself as a “behavior-change company.”  Simply put, Noom takes a lifestyle-based approach to weight loss, delving into the habits of its users and reorienting them towards healthier routines for diet and exercise. Building off that foundation, Noom then got into the GLP-1 prescription business in 2023. Armed with a subscription-based health app and a substantial ad spend for campaigns featuring celebrity spokesperson Rebel Wilson, Noom has raised nearly $660 million over 10 funding rounds since its founding in 2008. Yet like Weight Watchers, the company’s pivot in the age of GLP-1s hasn’t been without bumps along the way. Noom conducted mass layoffs in 2022 and 2025 amid a slowdown in its key business units. Still, the company is trudging forward.  This week, Noom CEO Geoff Cook returns to the show to chat with reporter Bella Czajkowski about the company’s plans for the future, how the GLP-1 treatment space needs to evolve and what their go-forward advertising strategy is.  For our Trends segment, we’re talking about a pair of recent Supreme Court rulings – the ‘skinny label’ case between Hikma and Amarin as well as Bayer’s Roundup decision – and what they mean for the healthcare industry. Ahead of our feature interview, you’ll hear from editorial director Jameson Fleming, who is back from his weeklong trip to cover Cannes. He’s got a full rundown of what you need to know about how medical marketing’s top work was received over there. Check us out at: mmm-online.com   Follow us:  YouTube: @MMM-online TikTok: @MMMnews Instagram: @MMMnewsonline Twitter/X: @MMMnews LinkedIn: MM+M   To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

    Can Noom rediscover its ad spend glory?

Ratings & Reviews

4.2
out of 5
11 Ratings

About

MM+M editors Jameson Fleming, Jack O'Brien, Bella Czajkowski, Lecia Bushak, and Steve Madden speak with people of note in and around the healthcare marketing world, and chat about news impacting the sector. New episodes released each week.

You Might Also Like